Home Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
 

Keywords :   


Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial

2015-02-09 18:35:24| Biotech - Topix.net

Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced enrollment of the 700th patient in the NeuVax Phase 3 PRESENT clinical trial. NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting.

Tags: present trial phase patient

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.11
26.11 DVD
26.11W102
26.11 821
26.11
26.112 19
26.11 BROOKS B17 CHAMPION
26.11ENCODER
More »